Nandrolone (17-Nortestosterone) And Glucose Metabolism: From Ugly Duckling To Handsome Swan.

Atul Dhingra, Sanjay Kalra, Nitin Kapoor

Journal: JPMA. The Journal of the Pakistan Medical Association 2025;75(4):654-656

PMID: 40269380

Abstract

Glucosarcopenia, or sarcopenia coexisting with diabetes, is a common condition. Caused by various factors, including poor glucose control, as well as some glucoselowering therapies, sarcopenia negatively impacts quality of life and long-term health. Nandrolone, or 19- nortestosterone, is a selective anabolic receptor modulator (SARM), classified as an anabolic-androgenic steroid (AAS). A review of its pharmacological properties suggests that it may be used as therapy for sarcopenia, along with medical nutrition therapy and resistance exercise training. This review suggests a practical and pragmatic approach towards ensuring safe and smart usage of nandrolone in glucosarcopenia management.

Address: Department of Endocrinology, Bharti Hospital, Karnal, India; University Center for Research & Development, Chandigarh University, Mohali, India.; Department of Endocrinology, Dr SS Tantia Medical College Hospital & Research Centre, Sriganganagar, India.; Department of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore, India; Non communicable disease unit, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.